Top-Rated StocksTop-RatedNASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $33.18 -1.03 (-3.01%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunocore alerts: Email Address About Immunocore Stock (NASDAQ:IMCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunocore alerts:Sign Up Key Stats Today's Range$33.14▼$34.4950-Day Range$32.98▼$41.4952-Week Range$32.37▼$76.98Volume353,695 shsAverage Volume577,199 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$80.40Consensus RatingModerate Buy Company OverviewImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More… Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Immunocore Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 52nd PercentileImmunocore scored higher than 52% of companies evaluated by MarketBeat, and ranked 557th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageImmunocore has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.79) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -27.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -27.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.15% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 16.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.15% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 16.22%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.15 News SentimentImmunocore has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Immunocore this week, compared to 3 articles on an average week.Search Interest4 people have searched for IMCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Immunocore is held by insiders.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address IMCR Stock News HeadlinesImmunocore (NASDAQ:IMCR) Price Target Lowered to $78.00 at Needham & Company LLCSeptember 18 at 4:51 AM | americanbankingnews.comImmunocore's (IMCR) Buy Rating Reaffirmed at HC WainwrightSeptember 18 at 4:51 AM | americanbankingnews.comHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.September 20, 2024 | DealMaker (Ad)TD Cowen Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)September 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunocore Holdings Amid Promising Clinical Results and Strategic ExpansionSeptember 16, 2024 | markets.businessinsider.comImmunocore Holdings plc (IMCR): Short Seller Sentiment is Bearish on This Cancer StockSeptember 15, 2024 | msn.comImmunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancerSeptember 14, 2024 | globenewswire.comSignificant Portfolio Addition: T. Rowe Price Investment Management, Inc.September 12, 2024 | finance.yahoo.comSee More Headlines IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $68.32 at the beginning of the year. Since then, IMCR stock has decreased by 51.4% and is now trading at $33.18. View the best growth stocks for 2024 here. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) posted its earnings results on Thursday, August, 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.25. The business's quarterly revenue was up 26.2% on a year-over-year basis. When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's top institutional shareholders include Primecap Management Co. CA (3.90%), Armistice Capital LLC (1.95%), Fiera Capital Corp (1.75%) and Renaissance Technologies LLC (1.29%). View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/20/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year FoundedN/APrice Target and Rating Average Stock Price Target$80.40 High Stock Price Target$100.00 Low Stock Price Target$66.00 Potential Upside/Downside+140.6%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-19.16% Pretax Margin-21.19% Return on Equity-14.68% Return on Assets-6.68% Debt Debt-to-Equity Ratio1.31 Current Ratio5.17 Quick Ratio5.15 Sales & Book Value Annual Sales$280.91 million Price / Sales5.95 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book4.50Miscellaneous Outstanding Shares50,012,000Free Float45,461,000Market Cap$1.67 billion OptionableOptionable Beta0.73 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IMCR) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.